Benitec Biopharma, NantWorks to collaborate on cancer program
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Essential IR Insights Newsletter - Summer July-August 2023
Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits
Benitec Biopharma Ltd. is in talks for a sub-license from Patrick Soon-Shiong's NantWorks to develop treatments for head and neck cancer using a gene silencing approach.
The company is negotiating terms of the collaboration with a targeted date for execution of Jan. 27, 2017.
